60 related articles for article (PubMed ID: 23659762)
1. Vascular function and glucose variability improve transiently following initiation of continuous subcutaneous insulin infusion in children with type 1 diabetes.
Harrington J; Peña AS; Wilson L; Gent R; Dowling K; Baghurst P; Couper J
Pediatr Diabetes; 2013 Nov; 14(7):504-11. PubMed ID: 23659762
[TBL] [Abstract][Full Text] [Related]
2. Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study.
Schreiver C; Jacoby U; Watzer B; Thomas A; Haffner D; Fischer DC
Clin Endocrinol (Oxf); 2013 Nov; 79(5):641-7. PubMed ID: 23134485
[TBL] [Abstract][Full Text] [Related]
3. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
4. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
5. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.
Choi SB; Lee JH; Lee JH; Kim S; Han SD; Kim IH; Noh YH
Diabetes Metab Res Rev; 2013 Sep; 29(6):473-82. PubMed ID: 23592489
[TBL] [Abstract][Full Text] [Related]
6. Benefits of continuous subcutaneous insulin infusion (CSII) therapy in preschool children.
Levy-Shraga Y; Lerner-Geva L; Modan-Moses D; Graph-Barel C; Mazor-Aronovitch K; Boyko V; Pinhas-Hamiel O
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):225-9. PubMed ID: 23329580
[TBL] [Abstract][Full Text] [Related]
7. [Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus].
Hasselmann C; Bonnemaison E; Faure N; Mercat I; Bouillo Pépin-Donat M; Magontier N; Chantepie A; Labarthe F
Arch Pediatr; 2012 Jun; 19(6):593-8. PubMed ID: 22584198
[TBL] [Abstract][Full Text] [Related]
8. [Benefits of subcutaneous continuous insulin infusion in type 1 diabetic patients with high glycemic variability].
Prieto-Tenreiro A; Villar-Taibo R; Pazos-Couselo M; González-Rodríguez M; Casanueva F; García-López JM
Endocrinol Nutr; 2012 Apr; 59(4):246-53. PubMed ID: 22440045
[TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus.
Opipari-Arrigan L; Fredericks EM; Burkhart N; Dale L; Hodge M; Foster C
Pediatr Diabetes; 2007 Dec; 8(6):377-83. PubMed ID: 18036064
[TBL] [Abstract][Full Text] [Related]
10. A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS.
Simon B; Treat V; Marco C; Rosenberg D; Joseph J; Hipszer B; Li Y; Chervoneva I; Padron-Massara L; Jabbour S
Int J Clin Pract; 2008 Dec; 62(12):1858-63. PubMed ID: 19166434
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
Sulli N; Shashaj B
Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
[TBL] [Abstract][Full Text] [Related]
12. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
Pickup JC; Sutton AJ
Diabet Med; 2008 Jul; 25(7):765-74. PubMed ID: 18644063
[TBL] [Abstract][Full Text] [Related]
13. Sustained metabolic control and low rates of severe hypoglycaemic episodes in preschool diabetic children treated with continuous subcutaneous insulin infusion.
Pańkowska E; Szypowska A; Lipka M; Skórka A
Acta Paediatr; 2007 Jun; 96(6):881-4. PubMed ID: 17537017
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment.
Talaviya PA; Saboo BD; Joshi SR; Padhiyar JN; Chandarana HK; Shah SJ; Vyas CK; Shah AN
Diabetes Metab Syndr; 2013; 7(2):68-71. PubMed ID: 23680243
[TBL] [Abstract][Full Text] [Related]
15. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes.
Peña AS; Couper JJ; Harrington J; Gent R; Fairchild J; Tham E; Baghurst P
Diabetes Technol Ther; 2012 Jun; 14(6):457-62. PubMed ID: 22313018
[TBL] [Abstract][Full Text] [Related]
18. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).
Shashaj B; Busetto E; Sulli N
Diabet Med; 2008 Sep; 25(9):1036-42. PubMed ID: 18937673
[TBL] [Abstract][Full Text] [Related]
19. The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.
Sahin SB; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
Acta Diabetol; 2010 Dec; 47(4):325-30. PubMed ID: 20842389
[TBL] [Abstract][Full Text] [Related]
20. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
